Pharm
Eribulin
search
Eribulin
, Halaven
See Also
Mitotic Inhibitor Chemotherapy
Chemotherapy
Indications
Metastatic
Breast Cancer
(refractory)
Metastatic
Liposarcoma
(refractory, non-resectable)
Mechanism
See
Mitotic Inhibitor Chemotherapy
Eribulin is a Halichondrin B analog with antineoplastic properties
Dervied from the marine sponge Lissodendoryx.
Eribulin is an anti-tubulin agent
Binds to tubulin (at vinca doman)
Inhibits tubulin polymerization and microtubule assembly
Arrests
Cell Cycle
at G2/M phase
Medications
Eribulin 1 mg/2ml intravenous solution
Dosing
See other references for disease specific dosing protocols
Adjust dosing in renal and hepatic
Impairment
Adults: 1.4 mg/m2 on days 1 and 8, in every 21 day cycles
Adverse Effects
Acute Life-threatening Hypersensitivity Skin Reaction
Stevens Johnson Syndrome
Toxic Epidermal Necrolysis
Pharmacokinetics
Hepatic excretion in feces unchanged
Safety
Avoid in
Lactation
Avoid in pregnancy (all trimesters)
Use reliable
Contraception
Resources
Eribulin Injection Solution (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=31ce4750-ded5-4a0b-95e9-f229fa6bc822
Type your search phrase here